港股异动 | 维亚生物(01873)再涨超13% AI制药领域高额合作频现 机构称公司AI制药平台优势明显

Group 1 - The core viewpoint of the article highlights that Viya Bio (01873) has seen a significant increase in its stock price, rising over 13% in a single day and accumulating a total increase of over 40% within the month [1][1][1] - The collaboration between Crystal Technology Holdings and DoveTree has set a new record for AI drug discovery orders, indicating a growing trend in the pharmaceutical industry towards AI-assisted drug development [1][1][1] - Shanxi Securities emphasizes that the large orders from multinational corporations (MNCs) to AI pharmaceutical companies validate the profitability of AI drug companies through technology licensing and revenue-sharing models, reflecting a strong demand from traditional pharmaceutical giants for AI-assisted R&D [1][1][1] Group 2 - According to Guoyuan International, Viya Bio has been investing in AI drug development for the past five years, with AI-related orders now accounting for 12% of new signed orders, showing a positive growth trend [1][1][1] - The company possesses self-developed algorithms and platform capabilities through its AIDD and CADD platforms, along with experience in developing various drug forms, leveraging its structural drug development advantages [1][1][1] - Viya is transitioning from a phase where computational methods empower various stages of drug development to a new phase driven by AI in drug design, aiming to change the paradigm of drug design [1][1][1]